Learn peptides step by step

GLP-1s and Breast Cancer Risk: What the New Signal Means

GLP-1 research is moving beyond weight loss. New breast cancer risk and survival signals are interesting, but they need careful interpretation.

GLP-1s Before Bariatric Surgery: What the 2026 Evidence Says

GLP-1 peptides are changing the bariatric surgery conversation. The practical lesson is not self-managing around surgery. It is better tracking, clearer handoffs, and coordinated medical planning.

Tirzepatide vs. Semaglutide: What the 2026 Data Actually Shows

New head-to-head trials and real-world data from 2025-2026 reveal tirzepatide and semaglutide are not equivalent - they produce meaningfully different outcomes depending on your goals.

GLP-1 Discontinuation: How to Maintain Weight Loss After Stopping

A 2025 Biomolecules review highlights the hardest GLP-1 question: what happens after the weight comes off? Maintenance needs a plan before the final dose.

GLP-1 Lean Mass Loss: What 2026 Data Shows

A new 2026 meta-analysis puts real numbers on lean mass change during semaglutide, tirzepatide, and liraglutide weight loss. The practical takeaway is not panic. It is better tracking.

GLP-1 Nutrition Strategy: Protein, Muscle, and Labs

New 2026 reviews show a nutrition gap in GLP-1 and incretin therapy research. Here is how to protect protein intake, lean mass, hydration, and labs while appetite is suppressed.

GLP-1 Food Noise: Why It Comes Back After Stopping and What Actually Helps

Food noise — that constant mental chatter about food — often comes back after stopping GLP-1 peptides. Here's the science of why, and what actually helps: maintenance strategies, stacking options, and realistic expectations.

GLP-1 for Weight Loss Without Diabetes: What the 2026 Systematic Review Found

You don't need to have diabetes to benefit from GLP-1 therapy. A comprehensive 2026 systematic review confirms what the peptide community has known for years — and the results are striking.

MOTS-C After Stopping GLP-1 Agonists: Dosing and Protocol Guide

Finished your GLP-1 cycle and want to maintain metabolic momentum? MOTS-C is one of the most effective peptides for supporting fat oxidation and energy during GLP-1 off-cycles. Here's how to dose and time it.

Switching from Tirzepatide to Retatrutide: The Complete Transition Guide

Already on tirzepatide and considering retatrutide? Here's exactly how to make the switch—starting doses based on your current Tirz level, what the glucagon component changes, and how to avoid common transition mistakes.

Why Your Weight Isn't Moving on Retatrutide (And What to Do About It)

Hitting a plateau on Retatrutide is common and usually temporary. Here's the science behind GLP-1 stalls and the practical steps to break through them.

AOD-9604: The HGH Fragment That Targets Fat Without the Side Effects

AOD-9604 is a synthetic fragment of human growth hormone designed specifically to stimulate fat breakdown without the glucose or IGF-1 side effects of full HGH. Here's how it works and who it's for.

Retatrutide Phase 3 Results: 28.7% Body Weight Reduction Sets a New Standard

Phase 3 trial data is in: retatrutide delivers 28.7% average body weight reduction, outpacing every approved GLP-1 therapy. The numbers tell a clear story about where metabolic medicine is heading.

11m

Why Retatrutide is Winning: Clinical Data Shows 28% Superior Fat Loss Over GLP-1

A 2026 meta-analysis comparing retatrutide to GLP-1 (Ozempic/Wegovy) and tirzepatide shows retatrutide delivers 28% superior fat loss. Here's the science behind why the triple-agonist approach is reshaping weight loss and body recomposition.

The Science of Retatrutide: How GLP-1/GIP/Glucagon Triple Agonists Work

Retatrutide's triple receptor mechanism simultaneously suppresses appetite, enhances metabolic function, and activates thermogenesis. Here's the science behind why it delivers 24% body weight reduction.

How Retatrutide Works: The Science Behind the Triple-Receptor Agonist

Retatrutide is not just a stronger tirzepatide. It's a fundamentally different molecule with three receptor targets instead of two. Here's how each mechanism contributes to rapid fat loss, metabolic optimization, and muscle preservation.

Why Retatrutide Preserves Muscle Better Than Tirzepatide

Rapid fat loss typically means muscle loss. But retatrutide's triple action—including glucagon receptor activation—preserves more lean mass than tirzepatide or GLP-1-only compounds. Here's the science.

12m

Retatrutide vs Tirzepatide: What the Latest Clinical Data Shows

Retatrutide and tirzepatide dominate the peptide conversation, but they're not interchangeable. Here's what the latest clinical research reveals about their differences, efficacy, and mechanisms.

Retatrutide Phase 3 Results: What the Clinical Data Tells Us

New Phase 3 data shows retatrutide delivering superior metabolic benefits. Here's what researchers found and why it matters.

Retatrutide Shows 23% Superior Weight Loss vs Tirzepatide in Phase 3 Trial

Retatrutide, the triple-action GLP-1/GIP/glucagon receptor agonist, outperforms tirzepatide by 23% in the latest human clinical trial—the most comprehensive weight loss comparison to date.

Retatrutide: The Triple-Action Weight Loss Peptide Explained

Retatrutide is a next-generation weight loss peptide targeting three metabolic pathways. Here's how it works and why it outperforms earlier GLP-1 therapies.

12m

GLP-1 Agonists for Metabolic Health: Clinical Evidence & Body Recomposition Strategy

GLP-1 agonists have revolutionized metabolic health. Learn how these peptides work, their effects on metabolism, and how to use them strategically for body composition goals.

Retatrutide 2-Year Weight Loss Durability: What the Latest Data Shows

Retatrutide is showing remarkable 2-year durability for weight loss. Here's what the science says and what it means for your protocol.